Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
出版年份 2023 全文链接
标题
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
作者
关键词
-
出版物
EClinicalMedicine
Volume 58, Issue -, Pages 101882
出版商
Elsevier BV
发表日期
2023-03-21
DOI
10.1016/j.eclinm.2023.101882
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Effect of Orlistat on Sterol Metabolism in Obese Patients
- (2022) Yu-Jin Kwon et al. Frontiers in Endocrinology
- Obesity Prevalence Among U.S. Adults During the COVID-19 Pandemic
- (2022) Brandon J. Restrepo AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Long Term Weight Loss Diets and Obesity Indices: Results of a Network Meta-Analysis
- (2022) Jana Jabbour et al. Frontiers in Nutrition
- Updated Meta-Analysis Assessing the Cardiovascular Efficacy of Tirzepatide
- (2022) Dimitrios Patoulias et al. AMERICAN JOURNAL OF CARDIOLOGY
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
- (2022) Yunfeng Yu et al. Frontiers in Cardiovascular Medicine
- Precision Medicine and Obesity
- (2021) Maria Daniela Hurtado A et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
- (2021) Qian Zhang et al. Cell Metabolism
- The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial
- (2021) Clare A. Whicher et al. DIABETES OBESITY & METABOLISM
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome
- (2021) Vian Ahmed Wasta Esmail et al. Arab Journal of Gastroenterology
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
- (2021) Domenica Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients with Lipodystrophy
- (2021) Andrew Grover et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta‐Analysis
- (2021) Xiang‐Guo Lei et al. Obesity
- Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta‐analyses
- (2021) Andrei C. Sposito et al. Obesity Reviews
- Asperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice
- (2021) Muhammad Ishaq et al. Frontiers in Endocrinology
- The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
- (2021) Makoto Fukuda DIABETES
- Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
- (2021) Mathies M. Jepsen et al. EXPERT OPINION ON EMERGING DRUGS
- Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight
- (2021) Roger S. McIntyre et al. JOURNAL OF AFFECTIVE DISORDERS
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity
- (2021) Esmeralda Capristo et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Longitudinal Trends in Body Mass Index Before and During the COVID-19 Pandemic Among Persons Aged 2–19 Years — United States, 2018–2020
- (2021) Samantha J. Lange et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Anti-obesity drug discovery: advances and challenges
- (2021) Timo D. Müller et al. NATURE REVIEWS DRUG DISCOVERY
- Use of prescription medications associated with weight gain among US adults, 1999‐2018: A nationally representative survey
- (2021) Craig M. Hales et al. Obesity
- Amylin as a Future Obesity Treatment
- (2021) Babak Dehestani et al. Journal of Obesity & Metabolic Syndrome
- Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
- (2020) Igho J. Onakpoya et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
- (2020) Thomas A. Wadden et al. Obesity
- Lorcaserin Departs, Leaving More Questions than Answers
- (2020) Rekha Kumar et al. Obesity
- Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials
- (2020) Long Ge et al. BMJ-British Medical Journal
- Obesity in adults: a clinical practice guideline
- (2020) Sean Wharton et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- The global burden of disease attributable to high body mass index in 195 countries and territories, 1990–2017: An analysis of the Global Burden of Disease Study
- (2020) Haijiang Dai et al. PLOS MEDICINE
- Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity
- (2020) Leo Sungwong Choi et al. INTERNATIONAL JOURNAL OF OBESITY
- Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials
- (2020) Harpreet S. Bajaj et al. DIABETES OBESITY & METABOLISM
- Factors affecting weight loss variability in obesity
- (2020) Robert Dent et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis
- (2020) Leonardo Andrade Mesquita et al. Obesity Reviews
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
- (2020) Karine Clément et al. Lancet Diabetes & Endocrinology
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
- (2019) Xavier Pi-Sunyer et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of Liraglutide Plus Phentermine in Adults with Obesity Following 1 Year of Treatment by Liraglutide Alone: A Randomized Placebo-Controlled Pilot Trial
- (2019) Jena Shaw Tronieri et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
- (2019) Natasha C. Bergmann et al. DIABETOLOGIA
- Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies
- (2019) Olivia M. Farr et al. DIABETES OBESITY & METABOLISM
- A randomized, placebo‐controlled crossover trial of phentermine‐topiramate ER in patients with binge‐eating disorder and bulimia nervosa
- (2019) Debra L. Safer et al. INTERNATIONAL JOURNAL OF EATING DISORDERS
- Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures – 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists
- (2019) Jeffrey I. Mechanick et al. Surgery for Obesity and Related Diseases
- Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
- (2019) Maddalena Grieco et al. Frontiers in Neuroscience
- Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
- (2019) Maria Mirabelli et al. International Journal of Environmental Research and Public Health
- Efficacy of Metreleptin for Weight Loss in Overweight and Obese Adults with Low Leptin Levels
- (2018) ALEX DEPAOLI et al. DIABETES
- Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials
- (2018) Mark Warren et al. DIABETES OBESITY & METABOLISM
- Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
- (2018) Gene-Jack Wang et al. INTERNATIONAL JOURNAL OF OBESITY
- Addressing Obesity in Aging Patients
- (2018) John A. Batsis et al. MEDICAL CLINICS OF NORTH AMERICA
- Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial
- (2018) Alessio Basolo et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
- (2018) Xuechan Lyu et al. Frontiers in Pharmacology
- Precision medicine: diagnosis and management of obesity
- (2018) Gema Frühbeck et al. Lancet Diabetes & Endocrinology
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke
- (2018) Subodh Verma et al. CIRCULATION
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- High Prevalence of Rare Monogenic Forms of Obesity in Obese Guadeloupean Afro-Caribbean Children
- (2017) Lydia Foucan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy
- (2016) Jean L. Chan et al. CLINICAL ENDOCRINOLOGY
- Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
- (2016) Per Lundkvist et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- The Psychosocial Burden of Obesity
- (2016) David B. Sarwer et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients
- (2016) Hannah Mathew et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study
- (2016) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Leptin sensitizer reverses obesity
- (2016) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Management of Obesity in Women
- (2016) Nadia N. Ahmad et al. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes
- (2015) Jennifer S. ten Kulve et al. DIABETES CARE
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Leptin and the brain: Influences on brain development, cognitive functioning and psychiatric disorders
- (2015) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
- (2014) L. van Bloemendaal et al. DIABETES
- Identification and Saturable Nature of Signaling Pathways Induced by Metreleptin in Humans: Comparative Evaluation of In Vivo, Ex Vivo, and In Vitro Administration
- (2014) Hyun-Seuk Moon et al. DIABETES
- Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release
- (2014) W. Timothy Garvey et al. DIABETES CARE
- Erratum: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2014) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Comparison of Weight Loss Among Named Diet Programs in Overweight and Obese Adults
- (2014) Bradley C. Johnston et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
- (2014) Sonja K. Billes et al. PHARMACOLOGICAL RESEARCH
- Identification, assessment, and management of overweight and obesity: summary of updated NICE guidance
- (2014) H. Stegenga et al. BMJ-British Medical Journal
- 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline for the Management of Overweight and Obesity in Adults: Implications and New Opportunities for Registered Dietitian Nutritionists
- (2014) Barbara E. Millen et al. Journal of the Academy of Nutrition and Dietetics
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues
- (2013) G-J Wang et al. INTERNATIONAL JOURNAL OF OBESITY
- Long-term Drug Treatment for Obesity
- (2013) Susan Z. Yanovski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults
- (2012) David H. Winslow et al. SLEEP
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance
- (2011) H.-S. Moon et al. DIABETES
- Gipr Is Essential for Adrenocortical Steroidogenesis; However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr-/- Mice
- (2011) H. E. Bates et al. DIABETES
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans
- (2011) E A Rabiner et al. MOLECULAR PSYCHIATRY
- Vitamin E and adiponectin: proposed mechanism for vitamin E-induced improvement in insulin sensitivity
- (2011) Brianna Gray et al. NUTRITION REVIEWS
- The Effect of Tesofensine on Appetite Sensations
- (2011) Jo-Anne Gilbert et al. Obesity
- Orlistat 60 mg Reduces Visceral Adipose Tissue: A 24-Week Randomized, Placebo-Controlled, Multicenter Trial
- (2011) Steven R. Smith et al. Obesity
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
- (2010) A Sjödin et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis
- (2009) Daphne P Guh et al. BMC PUBLIC HEALTH
- Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
- (2009) David J. Heal et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
- (2009) C. Daousi et al. CLINICAL ENDOCRINOLOGY
- Treatment of refractory obesity in severely obese adults following management of newly diagnosed attention deficit hyperactivity disorder
- (2009) L D Levy et al. INTERNATIONAL JOURNAL OF OBESITY
- Pharmacokinetics of Subcutaneous Recombinant Methionyl Human Leptin Administration in Healthy Subjects in the Fed and Fasting States
- (2008) Jean L Chan et al. CLINICAL PHARMACOKINETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation